Pfizer Inc. $PFE Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 5.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,805,659 shares of the biopharmaceutical company’s stock after selling 113,617 shares during the quarter. Calamos Advisors LLC’s holdings in Pfizer were worth $50,703,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC raised its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. United Bank increased its position in Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after buying an additional 6,415 shares in the last quarter. Sei Investments Co. raised its holdings in shares of Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after acquiring an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC raised its holdings in shares of Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $24.46 on Tuesday. The stock has a fifty day moving average price of $25.32 and a 200 day moving average price of $26.18. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The firm has a market capitalization of $139.41 billion, a P/E ratio of 18.67 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period in the prior year, the firm posted $0.92 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Wall Street Analyst Weigh In

A number of research firms recently commented on PFE. CICC Research assumed coverage on Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Bank of America lowered their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.50.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: A Phase 3 failure in a competing biotech program boosted Pfizer and other rivals, as investors saw a potential competitive benefit for the company. The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions (PFE)
• Positive Sentiment: Market commentary highlighted Pfizer as a discounted value stock, suggesting investors may be attracted to its lower valuation and dividend yield. Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?
• Positive Sentiment: Pfizer finished the latest session higher even as the broader market declined, reinforcing relative strength in the stock. Pfizer (PFE) Advances While Market Declines: Some Information for Investors
• Neutral Sentiment: Analysts remain broadly cautious, with recent coverage showing an average “Hold” rating on Pfizer, which suggests the market is still waiting for clearer growth catalysts. Pfizer Inc. (NYSE:PFE) Receives Average Rating of “Hold” from Analysts
• Negative Sentiment: BMO Capital Markets cut its price target on Pfizer, signaling somewhat softer expectations for the shares despite keeping an outperform rating. Pfizer price target lowered by BMO Capital Markets
• Negative Sentiment: Guggenheim also trimmed its price target on Pfizer, though it maintained a buy rating, reflecting slightly less upside in the near term. Pfizer price target lowered by Guggenheim

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.